Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...

Hims offers convenient and affordable access to treatments and products tailored for men's health needs. But how much does it ...

What initially stands out to me about Hims & Hers is the company's distinct branding and feel of luxury, which is evident on ...

Fintel reports that on January 7, 2025, BTIG initiated coverage of Hims & Hers Health (NYSE:HIMS) with a Buy recommendation.